Close Menu

More articles about Cancer

The company expects to garner clearance for its platform in the US first for Lynch syndrome as it builds additional evidence for an immunotherapy application.

Christiana Care researchers have identified a unique protospacer adjacent motif site that allows them to knock out the NRF2 gene in tumor cells while leaving normal cells alone.

The accelerated approval is based on results from two cohorts of a Phase II, single-arm trial in which EZH2-mutated patients had an overall response rate of 69 percent.

The work suggests mass spec can more accurately assess levels of immunotherapy targets like PD-L1 than conventional clinical approaches.

GNS Healthcare will apply its AI and simulation technology to data from the CoMMpass study in search of insights on disease progression and drug response.

The firm's technology uses ex vivo organ culture to model cancer growth and predict a patient's tumor response to chemotherapy and targeted drugs. 

ArcherDX said the firms aim to apply minimal residual disease monitoring in clinical-trial protocols and for future therapy optimization.

The launch of the company's Prism system earlier this month should support the development of an accompanying menu of tests to serve diverse users.

The accelerated approval is based on data showing that refractory cancer patients with TMB of at least 10 mutations/Mb saw tumor shrinkage and had durable responses on the immunotherapy.

The collaboration will allow oncologists a streamlined view of the treatments and trials available to patients based on their genomic profile.

Researchers from startup Duality Technologies and Dana-Farber have demonstrated the efficacy and speed of a highly secure technique for analyzing encrypted genomic data.

Dante Labs will use library preparation kits from Nonacus and software from CCG.ai to create a sample-to-report service, the firms said.

Lexent Bio's monitoring platform is in development and based on low-pass whole-genome sequencing and DNA methylation analysis.

The company is commercializing a genome-wide sequencing method called MRDetect, developed by researchers at the New York Genome Center and Weill Cornell Medicine. 

The Tucson, Arizona-based firm signed agreements with Denmark-based BioNordika, Czech Republic-based Explorea, and Bulgaria-based Elta 90.

At the American Society of Clinical Oncology's virtual meeting, investigators presented two new studies of BluePrint classification patterns.

The firm touts a new hybridization probe design, which it says will enable small, focused panels that reduce sequencing costs and assay time.

The bioinformatics vendor is customizing a multiomics health data platform to help pancreatic cancer researchers pursue new therapeutic targets.

Genetron's S5 sequencer is based on Thermo Fisher's Ion GeneStudio S5 instrument and is cleared for clinical use by China's NMPA.

Personalis said that it plans to form a wholly owned subsidiary in Shanghai, including a laboratory for local customers to use its ImmunoID NeXT platform.

Pages

Researchers have developed a robotic lab assistant, the Verge reports.

CBC News reports Canada's Supreme Court is to rule on the constitutionality of the country's genetic non-discrimination law today.

The Associated Press reports the World Health Organization is sending experts to China to investigate the animal source of SARS-CoV-2.

In Science this week: atlas of affected cell populations in idiopathic pulmonary fibrosis, and more.